Rescue dog Rosie’s cancer shrinks after world-first mRNA vaccine | The Australian

https://www.theaustralian.com.au/business/technology/tech-boss-uses-ai-and-chatgpt-to-create-cancer-vaccine-for-his-dying-dog/news-story/292a21bcbe93efa17810bfcfcdfadbf7

Scientists Discover Simple Trick That Boosts #mRNA Therapy Delivery 20-Fold

Scientists Discover Simple Trick That Boosts mRNA Therapy Delivery 20-Fold

💉 Moderna to Pay Up to $2.25B to Settle COVID Vaccine Patent Dispute

Moderna has agreed to pay up to $2.25 billion to resolve a long-running patent dispute with Genevant Sciences and Arbutus Biopharma over the lipid nanoparticle (LNP) technology used in its COVID-19 vaccine.

Under the agreement:

• $950 million will be paid upfront in July 2026
• Up to $1.3 billion more depends on the outcome of a separate legal appeal

The dispute centered on lipid nanoparticle (LNP) technology — the microscopic delivery system that protects fragile mRNA molecules and ensures they reach human cells effectively.

Importantly, Moderna will not owe royalties for LNP technology in future vaccines under this settlement.

📈 Market reaction:

• Moderna shares rose more than 10% (after-hours)
• Arbutus increased 11%
• Roivant gained about 1%

Analysts suggest the settlement removes a significant royalty risk and represents only a small portion of Moderna’s approximately $48 billion in past global vaccine sales.

⚖️ This deal also avoids what would have been the first U.S. trial over COVID vaccine patents — a case that could have set major precedents across the pharmaceutical industry.

💡 Bigger Picture:
This is another example of how critical intellectual property strategy is in biotech. Patent disputes can reshape markets, influence innovation timelines, and impact billions in revenue.

📌 Contact @ipconsultinggroup-1 For a Free tailored IP insights and legal guidance:
📧 protect@ipconsultinggroups.com
🌐 www.ipconsultinggroups.com
📞 DC: +1 (202) 666-8377 | MD: +1 (240) 477-6361

Accelerating mRNA Analytics with Mass Photometry

Producing messenger RNA (mRNA)-based therapeutics requires characterization by assessing critical quality attributes (CQAs) relating to potency, safety, identity, content, purity, and integrity. As an mRNA analytics tool, mass photometry is fast, accurate, easy to use, capable of single-molecule resolution, and able to analyze samples in their native state without denaturation.
Download this…

Accelerating mRNA Analytics with Mass Photometry

A Food and Drug Administration (FDA) dos Estados Unidos anunciou que irá realizar uma revisão formal da vacina contra a gripe baseada em mRNA da Moderna. Essa decisão marca uma mudança significativa no cenário da imunização e vem em resposta a uma série crescente de preocupações sobre a eficácia e a capacidade de resposta das vacinas contra a gripe tradicionais, especialmente em face de novas cepas de vírus que podem apresentar riscos pandêmicos. O movimento da FDA é visto como um passo em direção à inovação na tecnologia vacinal, que pode transformar a maneira como lidamos com surtos de influenza sazonais e pandemias futuras.(…)

Leia a noticia completa no link abaixo:

A recente rejeição nos Estados Unidos à nova vacina de gripe baseada em tecnologia mRNA acendeu um alerta entre especialistas em saúde pública e epidemiologistas, que estão preocupados com a possibilidade de uma resistência crescente a vacinações em um momento em que a proteção contra doenças respiratórias é mais crítica do que nunca. O objetivo dessa nova vacina é semelhante ao das vacinas desenvolvidas para COVID-19: utilizar a tecnologia mRNA para induzir uma resposta imunológica que proteja os indivíduos contra o vírus da gripe.(…)

Leia a noticia completa no link abaixo:

A recente decisão da Administração de Alimentos e Medicamentos dos EUA (FDA) de não revisar a aplicação da Moderna para a primeira vacina contra a gripe baseada em mRNA levantou um mar de controvérsias e críticas em várias frentes. A vacina, que poderia representar um grande avanço no combate às doenças respiratórias sazonais, não será analisada pelo órgão regulador, o que preocupa não apenas os especialistas da área da saúde, mas também a população em geral que já experimentou os efeitos devastadores da pandemia de COVID-19.(…)

Leia a noticia completa no link abaixo:

تقنية جديدة تعيد برمجة المناعة داخل الورم لقتل الخلايا السرطانية

تقنية جديدة تعيد برمجة المناعة داخل الورم لقتل الخلايا السرطانية

As empresas biotecnológicas Moderna e Merck anunciaram resultados animadores de sua vacina personalizada de mRNA contra o câncer, a qual demonstrou proteção com eficácia de cinco anos. Essa vacina, que é adaptada para atacar as características específicas de cada tumor, representa uma nova abordagem na luta contra essa doença devastadora. O anúncio foi feito em um recente congresso médico, gerando uma onda de otimismo entre pacientes, médicos e especialistas em saúde pública.(…)

Leia a noticia completa no link abaixo:

Everyone Is Trading MRNA Wrong — The Real Move Is Hidden Here | Set and Forget Trading

Saw a clean breakdown on MRNA that skips the noise completely.
No indicators, no news — just higher-timeframe supply & demand showing where the real move is forming.

Everyone Is Trading MRNA Wrong — The Real Move Is Hidden Here | Set and Forget Trading

Most traders are reading MRNA wrong. This video shows the real move using higher timeframes and pure price action.

Welcome to the mRNA Age by Moderna

Breakthrough Alert: World’s First Preventative Lung Cancer Vaccine Trials Set for 2026.

A new era in cancer prevention is approaching. According to Dr. Qiu Lixin from Fudan University Shanghai Cancer Center, the LungVax lung cancer vaccine—utilizing mRNA technology—will begin clinical trials next year. This vaccine aims to train the immune system to stop cancer recurrence in post-surgery patients.

At MedBridgeNZ, we are committed to keeping you informed on global medical advancements. As a premier medical concierge provider, we do not provide medical treatment, but we bridge the gap for international patients seeking top-tier resources. Discover how Medical Tourism China can help you access leading experts and potential clinical trials.

Read the full breakdown in our latest article:
LungVax Lung Cancer Vaccine: World’s First Preventative Trials Launching in 2026

ALT

Former CDC Director Calls for Removal of Covid mRNA “Vaccines” From the Market - 🔔 The Liberty Daily

mRNA Covid shots may boost the effects of certain cancer treatments, study suggests

Two major peer-reviewed population studies confirm the same alarming reality: vaccinated individuals are experiencing significantly higher risks of multiple cancers, and John Richardson says there may be a link between turbo cancers and the recent discovery that 100% of COVID shot recipients have microclots.

We Must Address the COVID Vax Cancer Epidemic | Daily Pulse Ep 149 - Zeee Media

Your immune system can be trained to fight cancer. In 2025, vaccines are making that happen.

Cancer vaccines are no longer experimental—they’re real treatments showing measurable benefits. Our new post explores how mRNA, CRISPR, and personalized delivery systems are helping patients live longer, healthier lives.

💡 Full article link in the comments 👇

#BanishCancer